For your patients with HR+HER2- mBC,

Start with KISQALI 600 mg—the starting dose with proven outcomes 

• KISQALI is given as 600 mg (3 x 200-mg tablets) orally, once daily (3 weeks on, 1 week off) with either¹:

  • An AI once daily (continuously); in men and premenopausal women, an LHRH agonist should also be administered according to current clinical practice guidelines; or 

  • Fulvestrant 500 mg intramuscularly on Days 1, 15, and 29, and once monthly thereafter; in men and premenopausal women, an LHRH agonist should also be administered according to current clinical practice guidelines 

• Patients should continue treatment until disease progression or unacceptable toxicity

• Please refer to the full Prescribing Information for fulvestrant

• Please refer to the full Prescribing Information for the recommended dose of the chosen AI

• KISQALI can be taken with or without food 

• Store refrigerated at 2°C to 8°C (36°F to 46°F). Excursions permitted between 2°C and 15°C (36°F and 59°F)

• After dispensing, patients may store at room temperature at 20°C to 25°C (68°F to 77°F) for up to 2 months

• Store tablets in the original blister pack

Starting dose modifications for hepatic and severe renal impairment¹

• The recommended starting dose is 400 mg once daily for patients with moderate or severe (Child-Pugh class B or C) hepatic impairment

• The recommended starting dose is 200 mg once daily for patients with severe renal impairment

Expert perspective on dosing and patient adherence in HR+/HER2- mBC

Dr Nick McAndrew shares his perspective on simple dose reductions with KISQALI and how to improve adherence in patients with HR+/HER2- mBC.